Congress orders investigation into drug middlemen's hidden price incentives

What it does

This bill directs the Government Accountability Office to study how prescription drug prices are used to calculate fees and payments between different players in the drug supply chain—including pharmacy benefit managers, drug wholesalers, pharmacies, and manufacturers. The study will examine whether these price-based payment structures create conflicts of interest that incentivize the use of higher-priced drugs. Within two years, the GAO must report findings and recommend legislative or administrative action to Congress.

Why we flagged it

The bill mandates a Government Accountability Office (GAO) study of compensation and pricing structures within the prescription drug supply chain, focusing on potential conflicts of interest and price-based incentive misalignment. It is fundamentally a transparency and investigative measure, not a direct regulatory or appropriations action.

What the text implies

• The study's findings could form the evidentiary basis for future legislation restricting or banning percentage-of-price compensation models, which would directly impact PBM revenue structures and potentially reduce drug prices paid by consumers and insurers.
• By explicitly examining conflicts of interest in price-based fee structures, the bill signals congressional concern that intermediaries may be incentivized to favor higher-priced drugs, potentially laying groundwork for fiduciary-duty reforms or transparency mandates.

The full analysis lists 4 implications of this text.

Who stands to gain

Pharmacy benefit managers (potential regulatory scrutiny may force business model changes); Drug manufacturers (potential upside if study recommends restrictions on PBM incentives to favor hig; Pharmacy chains (potential upside if study recommends transparency or fee reforms favoring retail ph